MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-024-11972-w

Медицинская библиотека · BMC cancer · 2024

Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).

Lim Sung Hee, Lee Keun-Wook, Kim Jae-Joon, Im Hyeon-Su, Kim In-Ho, Han Hye Sook, Koo Dong-Hoe, Cho Jang Ho, Maeng Chi Hoon, Lee Min-Young, Lee Hyo Jin, Kim Jwa Hoon, Park Sang Gon, Jung Joo Young, Shin Seong-Hoon, Kim Ki Hyang, Kim Hyeyeong, Oh So Yeon, Kang Minsu, Jung Minkyu, Rha Sun Young

Многоцентровое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer (AGC). This study aimed to compare the efficacy between ICI and irinotecan-based chemotherapy as third-line treatment in patients with AGC.

METHODS

We retrospectively reviewed patients with AGC, whose third-line treatment started between July 2019 and June 2021 at 17 institutions in Korea. The ICI group included patients who received nivolumab or pembrolizumab, and the irinotecan-based chemotherapy group included patients who received irinotecan or FOLFIRI (5-fluorouracil, leucovorin and irinotecan).

RESULTS

A total of 363 patients [n = 129 (ICI) and n = 234 (irinotecan-based chemotherapy)] were analyzed. The median progression-free survival was 2.3 and 2.9 months in ICI and irinotecan-based chemotherapy groups, respectively (p = 0.802). The median overall survival (OS) was 5.5 and 6.0 months in ICI and irinotecan-based chemotherapy groups, respectively (p = 0.786). For all patients included in this study, multivariable analysis showed that weight loss, peritoneal metastasis, low serum sodium or albumin, and short duration of second-line treatment were associated with inferior OS (p < 0.05). ICI showed significantly longer OS than irinotecan-based chemotherapy in patients without peritoneal metastasis. Whereas ICI showed significantly shorter OS in patients without PD-L1 expression than irinotecan-based chemotherapy.

CONCLUSIONS

No significant difference in survival outcome was observed between ICI and irinotecan-based chemotherapy as third-line treatment for AGC patients. ICI might be preferred for patients without peritoneal metastasis and irinotecan-based chemotherapy for patients with tumors without PD-L1 expression.

TRIAL REGISTRATION: This study was registered in the Clinical Trial Registry of Korea ( https://cris.nih.go.kr : KCT 0007732).

Для цитирования: Lim Sung Hee, Lee Keun-Wook, Kim Jae-Joon, Im Hyeon-Su, Kim In-Ho, Han Hye Sook, Koo Dong-Hoe, Cho Jang Ho, Maeng Chi Hoon, Lee Min-Young, Lee Hyo Jin, Kim Jwa Hoon, Park Sang Gon, Jung Joo Young, Shin Seong-Hoon, Kim Ki Hyang, Kim Hyeyeong, Oh So Yeon, Kang Minsu, Jung Minkyu, Rha Sun Young. Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).. BMC cancer. 2024. DOI: 10.1186/s12885-024-11972-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.